COVID-19: Miracle Drug May Reduce Demand For Vaccine

COVID-19: Miracle Drug May Reduce Demand For Vaccine

In a report filed by THE GAURDIAN, the Pharmaceutical Manufacturers Group of the Manufacturing Association of Nigeria (PMG-MAN) has hailed an experimental drug used for severe COVID-19 as it reduces the duration of being hospitalized or death as a result of COVID-19. Information Guide Nigeria

Interim clinical trial results reveal that the tablet which is called molnupiravir has been given to patients recently diagnosed with the disease.

As reported by THE GAURDIAN, Merck, a United States (U.S.) drug-maker, said its results were so positive that outside monitors had asked to stop the trial early. It said it would apply for the drugs to be approved for emergencies in the United States.

Chairman, PMG-MAN, Dr. Fidelis Ayebae, said, “This game-changing discovery puts a halt to all the craze for vaccine manufacturing temporarily. People now have more options. The progress made by Merck’s COVID-19 drug has sparked Asian vaccine stock selloff.”

Read Other Top Stories:

The Chairman revealed that if approved, the drugs, molnupiravir will be the first oral antiviral medication for COVID-19. Jamb Results

According to THE GAURDIAN originally, the pill was developed to treat influenza but has currently been designed to introduce errors into the genetic code of the virus, preventing it from spreading in the body.

An analysis of 775 patients in the study found: 7.3 per cent of those given molnupiravir were hospitalised; that compares with 14.1 per cent of patients who were given a placebo or dummy pill; and there were no deaths in the molnupiravir group, but eight patients who were given a placebo in the trial later died of COVID-19, THE GAURDIAN reports.

The previous trial of Molnupiravir suggests that it needs to be taken early after symptoms develop, to have an effect.

THE GAURDIAN reveals that Merck is the first company to report trial results of a pill to treat COVID-19 but other companies are working on similar treatments. Its U.S. rival, Pfizer, has recently started late-stage trials of two different antiviral tablets, while Swiss company Roche is working on a similar medication.

In addition, Merck has said that he expects to produce 10 million courses of Molnupiravir by the end of 2021. The U.S. government has already agreed to buy $1.2 billion (£885m) worth of the drug if it receives approval from the regulatory body, the Food and Drug Administration (FDA).

As reported by THE GUARDIAN, the company says it is in discussions with other countries, including the UK, and has also agreed licensing deals with a number of generic manufacturers to supply the treatment to low and middle-income countries.

Check and Confirm: How much is Dollar to Naira Today         Pounds to Naira Today



👍Showcase your business here!

With over 1M unique users per month across all channels, we have a large audience for you to showcase your products and services. Simply get in touch via 👉 marketing@Infoguidenigeria.com.


🤑 Make Money now!

👉 Make money writing for us. Apply for Freelance writing jobs in Nigeria.

👉 Make Money as InfoGuideNigeria Advertising Agents, read more here


✍️ Be Our Guest Publisher!

Do you have a press release, breaking news,  or any other helpful information to share with our growing readers? If yes, send your article to 👉 infoguidepr@gmail.com.

We will be glad to publish it if the information is useful to our audience.


This post can be helpful to somebody else, please share it on Facebook, Whatsapp, Telegram and Twitter. There are buttons below for this (easy to use too)!

Copyright Warning!

Contents on this website may not be republished, reproduced, redistributed either in whole or in part without due permission or acknowledgment.
Proper acknowledgment includes, but not limited to (a) LINK BACK TO THE ARTICLE in the case of re-publication on online media, (b) Proper referencing in the case of usage in research, magazine, brochure, or academic purposes,.
All contents are protected by the Digital Millennium Copyright Act 1996 (DMCA).
We publish all contents with good intentions. If you own this content & believe your copyright was violated or infringed, please contact us at [infoguidenigeria@gmail.com] to file a complaint and we will take necessary actions immediately.

Idongesit Akpa-Ayang

Idongesit is a graduate of Communication Arts, University of Uyo. Currently working as a news reporter at InfoGuide Nigeria.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button